Treatment of Acute Stage of Kawasaki Disease Based on Updated 2024
Open Access
- 31 December 2025
- journal article
- Published by Korean Society of Kawasaki Disease in Kawasaki Disease
- Vol. 3 (2)
Abstract
Kawasaki disease (KD) is an acute febrile illness that primarily affects children under five years of age and can lead to coronary artery aneurysms if left untreated. High-dose intravenous immunoglobulin (IVIg) is the standard treatment. However, approximately 10%–20% of patients are refractory to this therapy and require additional treatments, including biologic agents such as infliximab, etanercept, or anakinra. As the use of these biologic agents has increased in recent years, concerns have been raised that biologics may suppress immune responses, potentially compromising the safety and immunogenicity of subsequent vaccinations, particularly live-attenuated vaccines. This study outlines the principles of vaccination in children with KD who have received biologic therapy. Key factors such as pharmacokinetics, mechanisms of action, and the duration of immunosuppressive effects should be considered when determining the optimal timing for vaccination. In patients with KD, biologics are typically administered once, often following IVIg, which may reduce the risk of vaccine-related adverse events while still allowing for adequate antibody responses. Further research is needed to establish evidence-based guidelines for safe and effective immunization in these patients.Keywords
This publication has 28 references indexed in Scilit:
- 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesArthritis Care & Research, 2023
- Efficacy of live attenuated vaccines after two doses of intravenous immunoglobulin for Kawasaki diseaseWorld Journal of Pediatrics, 2022
- Safety and Feasibility of Infliximab Therapy in Children With Kawasaki Disease Who Received Live VaccinationsThe Pediatric Infectious Disease Journal, 2022
- Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature ReviewPediatric Drugs, 2020
- Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin–Resistant Kawasaki DiseaseArthritis & Rheumatology, 2020
- Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki DiseaseThe Pediatric Infectious Disease Journal, 2020
- European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiativeRheumatology, 2018
- Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease PatientsThe Pediatric Infectious Disease Journal, 2017
- Kawasaki syndromeThe Lancet, 2004
- Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-γ in Kawasaki disease involved coronary-artery lesionsClinical Immunology and Immunopathology, 1990